These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease. Reid TE; Kumar K; Wang XS Curr Top Med Chem; 2013; 13(11):1353-62. PubMed ID: 23675941 [TBL] [Abstract][Full Text] [Related]
6. Serotonin (5-HT) Shapes the Macrophage Gene Profile through the 5-HT Nieto C; Rayo I; de Las Casas-Engel M; Izquierdo E; Alonso B; Béchade C; Maroteaux L; Vega MA; Corbí ÁL J Immunol; 2020 May; 204(10):2808-2817. PubMed ID: 32253244 [TBL] [Abstract][Full Text] [Related]
7. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes. Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists. Padhariya K; Bhandare R; Canney D; Velingkar V Cardiovasc Hematol Disord Drug Targets; 2017; 17(2):86-104. PubMed ID: 28676029 [TBL] [Abstract][Full Text] [Related]
9. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones. Brea J; Rodrigo J; Carrieri A; Sanz F; Cadavid MI; Enguix MJ; Villazón M; Mengod G; Caro Y; Masaguer CF; Raviña E; Centeno NB; Carotti A; Loza MI J Med Chem; 2002 Jan; 45(1):54-71. PubMed ID: 11754579 [TBL] [Abstract][Full Text] [Related]
10. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Hofmann C; Penner U; Dorow R; Pertz HH; Jähnichen S; Horowski R; Latté KP; Palla D; Schurad B Clin Neuropharmacol; 2006; 29(2):80-6. PubMed ID: 16614540 [TBL] [Abstract][Full Text] [Related]
11. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. Kim SK; Li Y; Abrol R; Heo J; Goddard WA J Chem Inf Model; 2011 Feb; 51(2):420-33. PubMed ID: 21299232 [TBL] [Abstract][Full Text] [Related]
12. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Launay JM; Hervé P; Peoc'h K; Tournois C; Callebert J; Nebigil CG; Etienne N; Drouet L; Humbert M; Simonneau G; Maroteaux L Nat Med; 2002 Oct; 8(10):1129-35. PubMed ID: 12244304 [TBL] [Abstract][Full Text] [Related]
13. Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. Banes AK; Watts SW BMC Pharmacol; 2003 Sep; 3():12. PubMed ID: 12974983 [TBL] [Abstract][Full Text] [Related]
14. Development of Pharmacophore Models for the Important Off-Target 5-HT Schieferdecker S; Vock E J Med Chem; 2023 Jan; 66(2):1509-1521. PubMed ID: 36621987 [TBL] [Abstract][Full Text] [Related]
15. Structure activity relationship exploration of 5-hydroxy-2-(3-phenylpropyl)chromones as a unique 5-HT Kim M; Truss M; Pagare PP; Essandoh MA; Zhang Y; Williams DA Bioorg Med Chem Lett; 2020 Nov; 30(21):127511. PubMed ID: 32853682 [TBL] [Abstract][Full Text] [Related]
16. Further evidence that 5-HT-induced relaxation of pig pulmonary artery is mediated by endothelial 5-HT(2B) receptors. Glusa E; Pertz HH Br J Pharmacol; 2000 Jun; 130(3):692-8. PubMed ID: 10821800 [TBL] [Abstract][Full Text] [Related]
20. Serotonin-2B receptor antagonism increases the activity of dopamine and glutamate neurons in the presence of selective serotonin reuptake inhibition. Hamati R; El Mansari M; Blier P Neuropsychopharmacology; 2020 Nov; 45(12):2098-2105. PubMed ID: 32473594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]